2 Information about pralsetinib

Marketing authorisation indication

2.1 Pralsetinib (Gavreto, Roche) is indicated for 'the treatment of adult patients with rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitor'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics for pralsetinib.


2.3 The list price for 120 capsules of pralsetinib (100 mg) is £7,044 (excluding VAT, company submission).

2.4 The company has a commercial arrangement, which would have applied if the technology had been recommended.